Interventional Radiology Imaging

What Imaging Is Best for Surveillance of Node-Negative Cutaneous Melanoma?

·
What Imaging Is Best for Surveillance of Node-Negative Cutaneous Melanoma?

It’s a routine follow-up visit on a Tuesday afternoon. Your patient, a 58-year-old man, is two years out from a wide local excision of a Stage IIB melanoma on his shoulder. His sentinel lymph node biopsy was negative, and he has remained asymptomatic with clear skin exams ever since. He asks, “Shouldn’t we be doing a scan to make sure it hasn’t come back somewhere else?” This raises a critical question in oncology: what is the role of imaging in the surveillance of an asymptomatic, clinically node-negative melanoma patient? While guidelines emphasize clinical follow-up, certain imaging studies are considered in higher-risk subsets. For detecting potential asymptomatic brain metastases, the American College of Radiology (ACR) Appropriateness Criteria rates `MRI head without and with IV contrast` as ‘May be appropriate’ for this specific surveillance scenario. This article details the workflow and rationale for this decision.

Who Fits This Clinical Scenario for Melanoma Surveillance?

This guidance applies specifically to adult patients in the surveillance phase after initial treatment for cutaneous or muco-cutaneous melanoma. The defining characteristics for this workflow are:

  • Established Diagnosis: The patient has a known history of melanoma that has been surgically excised.
  • Negative Nodal Status: At the time of initial diagnosis and staging, there was no clinical or surgical evidence of regional lymph node involvement (e.g., a negative sentinel lymph node biopsy) or distant metastatic disease.
  • Asymptomatic Surveillance: The patient has no new signs or symptoms suggestive of recurrence or metastasis. The consideration for imaging is purely for surveillance.

It is crucial to distinguish this scenario from others that require a different imaging approach. This workflow does not apply to:

  • Initial Staging: A newly diagnosed patient who has not yet undergone definitive staging.
  • Known Nodal or Metastatic Disease: Patients who were found to have positive regional lymph nodes or distant metastases at their initial diagnosis.
  • Suspected Recurrence: Patients presenting with new, concerning symptoms such as a palpable lump, persistent cough, unexplained weight loss, or new focal neurologic deficits. This presentation shifts the workup from surveillance to an evaluation for suspected recurrence, which follows a different ACR pathway.
  • Ocular Melanoma: This is a distinct entity with its own specific staging and surveillance guidelines.

What Are You Looking for with Surveillance Imaging in Melanoma?

In this asymptomatic, node-negative patient population, surveillance imaging is not universally performed. Its use is often risk-stratified based on the primary tumor’s characteristics (e.g., Breslow depth, ulceration), with imaging more frequently considered for patients with higher-risk Stage IIB and IIC disease. The goal is the pre-symptomatic detection of distant metastases to potentially improve outcomes, though the evidence for a survival benefit from routine imaging remains debated. The primary targets of surveillance imaging reflect melanoma’s common patterns of spread.

Brain Metastases: Melanoma has a significant propensity to metastasize to the central nervous system (CNS). These lesions can be clinically silent until they grow large enough to cause mass effect or seizures. Detecting them at a small, asymptomatic stage may allow for more effective local treatment options like stereotactic radiosurgery. This is the principal rationale for considering brain imaging.

Pulmonary Metastases: The lungs are one of the most common sites of distant melanoma spread. Early pulmonary nodules are typically asymptomatic and only detectable on cross-sectional imaging. This is the primary target when considering chest imaging.

Hepatic, Adrenal, and Distant Nodal Metastases: The liver and adrenal glands are other frequent visceral sites for hematogenous spread. Non-regional lymph nodes can also be involved. These sites are typically evaluated with whole-body or torso imaging techniques.

Subcutaneous or Muscular Metastases: In-transit or distant soft tissue metastases can occur anywhere in the body. While a thorough physical exam is the primary screening tool, imaging, particularly FDG-PET/CT, can detect deep or otherwise occult lesions.

Why Is Brain MRI Considered for Surveillance in Node-Negative Melanoma?

For the specific task of detecting asymptomatic brain metastases in this surveillance setting, the ACR designates `MRI head without and with IV contrast` as ‘May be appropriate’. This rating reflects a balance between the modality’s high sensitivity and the relatively low pre-test probability of disease in the overall node-negative population. The decision to image is therefore highly dependent on individual risk assessment.

The rationale for this recommendation is rooted in several key factors:

  • Superior Sensitivity for Brain Parenchyma: MRI is the most sensitive non-invasive imaging modality for detecting brain metastases, especially small lesions. The addition of gadolinium-based IV contrast is critical, as melanoma metastases are typically hypervascular and enhance avidly, making them more conspicuous against normal brain tissue.
  • Lack of Ionizing Radiation: Surveillance may involve serial imaging over several years. MRI (adult_rrl=O 0 mSv) avoids the cumulative radiation exposure associated with CT scans, a significant advantage for long-term follow-up.

Alternative studies receive lower or different ratings for specific reasons in this context:

  • FDG-PET/CT whole body is also rated ‘May be appropriate’. While excellent for detecting systemic disease, its sensitivity for small brain metastases is lower than that of a dedicated brain MRI. Some institutions perform PET/MRI to combine the strengths of both, but PET/CT is more common. It involves significant radiation exposure (adult_rrl=☢☢☢☢ 10-30 mSv).
  • CT head with IV contrast is rated ‘Usually not appropriate’. While faster and more accessible than MRI, CT has lower intrinsic soft-tissue contrast and is less sensitive for detecting small parenchymal metastases, particularly in the posterior fossa. It is generally reserved for patients with contraindications to MRI.

Ultimately, the term ‘May be appropriate’ signifies that the ordering clinician must weigh the patient’s specific risk (e.g., Stage IIC vs. Stage IIA) against the potential yield of the study. For a patient with high-risk features, the potential benefit of detecting an asymptomatic, treatable brain metastasis may justify surveillance MRI.

What’s Next After MRI head without and with IV contrast? Downstream Workflow

The results of a surveillance brain MRI will dictate the subsequent clinical pathway. The workflow branches based on whether the findings are negative, positive, or indeterminate.

If the MRI is negative: For a patient who remains asymptomatic, a negative scan is reassuring. The next step is to continue the established clinical and dermatologic surveillance schedule as recommended by NCCN or other societal guidelines. The decision to repeat imaging in the future (e.g., annually for a defined period) depends on the initial risk assessment and institutional protocols.

If the MRI is positive for metastases: The identification of one or more lesions consistent with brain metastases requires urgent multidisciplinary consultation. The patient’s care should be escalated to a team including neurosurgery, radiation oncology, and medical oncology. Further management may include stereotactic radiosurgery (SRS) for a limited number of lesions, whole-brain radiation therapy (WBRT) for extensive disease, or systemic therapy. A whole-body staging study, such as an `FDG-PET/CT whole body`, would also be indicated to assess for other sites of metastatic disease.

If the MRI is indeterminate: Occasionally, a finding may be equivocal (e.g., a tiny enhancing focus of unclear etiology). In this situation, the next step is typically a short-interval follow-up MRI (e.g., in 6-12 weeks) to assess for stability or growth. If the lesion grows or develops features more typical of a metastasis, the patient would proceed down the “positive” pathway. If it remains stable or resolves, it is less likely to be malignant.

Pitfalls to Avoid (and When to Get Help)

When ordering surveillance imaging for melanoma, several common pitfalls can compromise diagnostic value or lead to unnecessary testing. Be mindful of the following:

  • Omitting IV Contrast: Ordering a non-contrast brain MRI for metastasis detection is a critical error. Many melanoma metastases are isointense to brain parenchyma on non-contrast sequences and only become visible after the administration of gadolinium.
  • Inappropriate Modality Choice: Do not substitute a head CT for an MRI to screen for asymptomatic brain metastases unless the patient has a strong contraindication to MRI (e.g., an incompatible implanted device). The lower sensitivity of CT could miss small, treatable lesions.
  • Imaging Low-Risk Patients: Routine surveillance imaging is generally not recommended for patients with low-risk disease (e.g., Stage I or IIA melanoma) due to the very low probability of finding asymptomatic metastases. Adhere to risk-stratified guidelines to avoid over-testing.

If you discover findings suggestive of metastatic disease, the situation requires prompt escalation. A positive finding should trigger immediate consultation with the patient’s medical oncology team and appropriate specialists (e.g., neurosurgery for brain metastases) to coordinate further workup and treatment planning.

Related ACR Topics and Tools

For a comprehensive overview of imaging across all clinical presentations of melanoma, from initial staging to suspected recurrence, please see our parent guide. It provides a valuable breadth-first look at the entire topic, whereas this article focuses on the depth of one specific scenario. Additional tools can help refine your imaging orders and facilitate discussions with patients.

Frequently Asked Questions

Is routine imaging recommended for all node-negative melanoma patients in surveillance?

No. Routine surveillance imaging is not recommended for all patients. Its use is typically reserved for higher-risk subgroups, such as those with Stage IIB or IIC disease, where the risk of distant recurrence is higher. For lower-risk patients, the potential harms of false positives and radiation exposure (from CT or PET/CT) generally outweigh the low probability of detecting asymptomatic disease.

If I’m considering systemic surveillance, should I order a PET/CT instead of separate brain and body imaging?

FDG-PET/CT is also rated ‘May be appropriate’ for this scenario and is an excellent tool for whole-body staging. However, it is less sensitive than a dedicated contrast-enhanced brain MRI for detecting small brain metastases. Some centers may opt for a PET/CT for systemic staging and a separate brain MRI for CNS evaluation, particularly in high-risk patients.

How often should surveillance imaging be performed if we decide to do it?

There is no universal consensus on the optimal frequency of surveillance imaging. Schedules are often determined by institutional protocols and national guidelines (like NCCN), which may suggest imaging (e.g., every 6-12 months) for a limited duration (e.g., 2-5 years) for high-risk patients. The decision should be individualized based on the patient’s specific risk factors and a shared decision-making conversation.

What if my patient develops a new symptom, like a cough, during surveillance?

The development of a new, persistent symptom changes the clinical scenario from ‘surveillance’ to ‘evaluation of suspected recurrence.’ In this case, you should not follow the surveillance workflow. The ACR has a separate variant for suspected recurrence, which would typically involve targeted imaging of the symptomatic area and/or systemic staging with a study like FDG-PET/CT.

Does this guidance apply to mucosal melanoma as well?

Yes, the ACR scenario explicitly includes both cutaneous and muco-cutaneous melanoma. Mucosal melanomas are often considered higher risk than their cutaneous counterparts, and surveillance imaging may be more strongly considered in these patients, even with clinically negative nodes at diagnosis.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026